Tag Archive for: Central Nervous System

The French pharma company continues to pare down its central nervous system business by divesting 11 brands to U.K.-based Pharmanovia, which is expanding its neurology portfolio.

Rykindo is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma’s central nervous system product portfolio to be marketed in the United States.

Xenpozyme is the first approved medication to treat symptoms that are not related to the central nervous system in patients with ASMD, a rare genetic disease that causes premature death.

There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.

Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer’s disease Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer’s; 24-week […]